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ABSTRACT:
Introduction: The patients with persistent forms of
Helicobacter pylori (HP) infection are refractory to eradica-
tion treatment. They receive unsuccessful therapies, experi-
ence frequent recurrences and re-infections. One of the main
reasons for the development of persistent forms is an inad-
equate and insufficient treatment. The persistent forms of HP
infection create conditions for   the maintenance of activity
and for the progression of the induced chronic gastritis. In
this aspect these cases will be at a higher risk for the devel-
opment of gastric cancer.
 The aim of this study is: to monitor and analyze the
cases with persistent HP infection and to establish an ap-
proach for their management.
 Clinical material and methods: The study includes
12 patients (8 female and 4 male) at a middle age of 63,7,
with a persistent HP infection, who have been observed for
a period of five years. Two methods for the detection of HP
infection are used – one invasive and one non-invasive. Up-
per endoscopy with morphological examination was per-
formed.
Results: In 9/12 patients HP was unsuccessfully
treated for three times, in 2 patients – four times, and in 1
patient – five times. In all patients the initial treatment con-
sisted of a standard triple therapy (STT). In 5 of them STT
was conducted  twice, with the same regimen for a period of
seven days. Two patients received  three courses of  STT. In
four patients an antibiotic resistance was established by
means of a cultured assessment. In three cases an HP resist-
ance to Clarithromycine and Metronidazole was demon-
strated. Significant gastro-duodenal pathology with atrophic
gastritis, intestinal metaplasia, and hyperplastic polyposis
was found in all patients.  The persistent clinical symptoms
had 9 patients.
Conclusion: We believe that a devised and proposed
step strategy which covers early detection of infection, reli-
able diagnosis, adequate and successful treatment, and dis-
pensary monitoring, contributes to the prevention of gastric
cancer.
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The patients with persistent forms of Helicobacter py-
lori (HP) infection are usually refractory to standard eradi-
cation treatment. They receive unsuccessful therapies, ex-
perience frequent recurrences and re-infections. One of the
main reasons for the development of persistent forms is an
inadequate and insufficient treatment. The persistent forms
of HP infection create conditions for the maintenance of ac-
tivity and for the progression of the induced chronic gastri-
tis. In this aspect these cases will be at a higher risk for the
development of gastric cancer.
 The aim of this study:
· to monitor and analyze the cases with persistent HP
infection
· to establish an approach for their diagnosis, man-
agement and treatment.
PATIENTS AND METHODS:
The study includes 12 patients (8 female and 4 male),
at a middle age of 63,7, with a persistent HP infection, who
have been observed for a period of five years.
HP infection was proven and unsuccessfully treated
three times consequtively  in 9/12 patients,  four times in 2/
12 patients and  five times in 1/12 patients.
Two methods for the detection of HP infection are
used – one invasive and one non-invasive (by histology and
fecal antigen test). Upper endoscopy with morphological
examination was performed. Cultured assessment for HP in-
fection was performed in 7 patients. Was used a disk diffu-
sion method, taking into account areas of dwarfed.  Assess-
ment for HP in the dental plaque was made by the PCR- DNA
method. Quality of life in all patients by a questionnaire con-
taining 14 questions was examined.
RESULTS:
Analysis of the treatment
All patients had initial treatment with standard triple
therapy (STT). In 9/12 patients HP was unsuccessfully treated
for three times, in 2 patients – four times, and in 1 patient –
five times.
In 5 of them STT was conducted twice, with the same
regimen for a period of seven days.
The next course after failed STT in 7/12patients was
sequential therapy. The history for frequent antibiotic use
had 7 patients. In four patients an antibiotic resistance was
established.
In three cases a combined HP resistance to
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Clarithromycine and Metronidazole was demonstrated.
In 5 patients side effects, mainly diarrhea, were re-
ported. In 4 patients poor compliance was achieved.
Clinical data:
Persistent clinical symptoms were present in 75% (9/
12) patients, predominantly epigastric pain. Episodes of re-
bleeding from the gastrointestinal tract (respectively 4 and
2 episodes) were observed in 2/12 patients. All patients had
a poor quality of life (bellow 25 points). None of the pa-
tients had other risk factors. In 3/12 patients a combination
of HP infection in the stomach and in the oral cavity (den-
tal plaque) was found. In 4 patients (3 female, 1male) de-
pressive symptoms were present. Two of all had a family his-
tory of gastric cancer.
Endoscopy and morphology data:
In all patients significant gastro-duodenal pathology
was found.
• chronic atrophic gastritis in 3 patients.
• antral atrophic gastritis with intestinal metaplasia
in 4 patients.
• antral atrophic gastritis with intestinal metaplasia
and dysplasia in 2 patients.
• atrophic gastritis with intestinal metaplasia and hy-
perplastic polyposis was found in 1 patient
• MALT Lymphoma in 1 patient
• atrophic pangastritis with Vitamin. B12 deficiency
anemia in 1 patient.
RESULTS OF TREATMENT:
In 4 patients .after antibiotic testing a quadruple per-
sonalized therapy was applied. In 4 patients quadruple se-
quential Levofloxacine based therapy was prescribed. Quad-
ruple Rifabutine based therapy plus Levofloxacine was
administred in 4 patients
A probiotic - Bio Gaia, was added as an adjuvant
therapy for period of 1 month.
• Successful eradication was established in all patients
after treatment
• The monitoring will continue
• All  have  been included in a register for gastric can-
cer risk patients
• HP infection is monitored every 6 months
• Sanitation of oral cavity and dental status is obliga-
tory.
• Endoscopic surveillance of patients with premalig-
nant lesions was carried out.
DISCUSSION:
Persistent forms of HP infection are those cases which
are refractory to standard  eradication regimes  and proven
for 2 years or more after unsuccessful therapy. According to
literature data [1, 2] their frequency ranges between 15-30%
of cases. Our data show nearly 12% incidence of persistent
HP infection.  We tend to assume that one of the main rea-
sons for the development of induced persisting forms is an
inadequate and/or insufficient treatment. Patients with per-
sistent forms of HP infection are refractory to a series of an-
tibiotic treatment. Common causes are insufficiency of treat-
ment period, interruption mode, failure mode and the pres-
ence of side effects. Such causes and circumstances were
found in our cases too. Our observation shows that frequent
re-prescription of the same eradication regimen is one of the
reasons for the development of secondary antibiotic resist-
ance. According to our observations the most frequent prac-
tice is the repeated administration of STT. In one of our cases
STT was appointed four times. Not by chance antibiotic re-
sistance to Clarithromycin and Metronidasole occurs most
frequently after this treatment pattern. Our results show that
the best strategy for the diagnosis and successful treatment
of persistent HP infection is a microbial culture with antibi-
otic testing, and a corresponding therapy.
According to J. Luther et al. [3] the treatment of per-
sistent infection with H. pylori is a major challenge for clini-
cal medicine today. Unfortunately the widely used triple
combination for 7 days, and 14 days in developed countries,
failed to successfully eliminate the infection and thus it per-
sists in not less than 25% of the patients. Significant gastro-
duodenal pathology - chronic active inflammation and pre-
malignant lesions. was found in all our patients
Muller et al [2] consider that persistent infection with
HP worsens inflammation and predisposes to an increased
risk of gastric cancer. According to the data of SS Kim et al.
[4] and Alvi et al.[5], that H. pylori stimulates gastric neo-
plasia mainly by inducing intense and prolonged inflamma-
tory response. This persistent state of chronic inflammation
causes oxidative stress, and adaptations in the pathobiology
of gastric epithelial and immune cells, which in a small
number of subjects would result in a marked neoplastic
transformation. S. Abdiev et al. [6] investigated the relation-
ship between persistent infection with H. pylori and gastric
atrophy, on the one hand, and the genetic polymorphism of
cytokines on the other hand.
Persistent forms create condition for persistence of
chronic inflammation, that stimulates gastric atrophy and in
this aspect presents a risk of gastric cancer. Cervantes et al.
[7] established that H. pylori infection of elderly relatives
always precedes persistent infection in the younger ones.
Study of the status of breastfeeding mothers, use of antibi-
otics and socioeconomic factors showed a strong effect of
persistent infection in older brothers and sisters on younger
siblings. Based on the results of our study, we register and
follow up the patients with persistent forms of HP infection,
because they have a higher risk for development of gastric
cancer and are subject to active surveillance in order to pre-
vent gastric cancer. Lee et al. [8] reported that HP-eradica-
tion has a substantially increasing importance especially for
the primary and secondary prevention of associated serious
diseases such as gastric cancer and gastric MALT lymphoma.
Based on our results, we consider that in order to pre-
vent the development of persistent form of infection, it will
be necessary to implement the following measures:
• more frequent check-up for HP infection at 6
months.;
• rehabilitation of potential sources of re-infection
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• testing of family members and improved sanitation
and hygienic status
• reliable verification of infection by at least two
methods
• appropriate and timely treatment of HP infection,
excluding re-administration of the same eradication regimen,
administration with the inclusion of two new antibiotics.
• endoscopic and morphological verification of the
associated gastro-duodenal pathology
• endoscopic surveillance of patients at risk for gas-
tric cancer
• treatment of active gastric inflammation
CONCLUSIONS:
Based on our observation and analysis of cases with
a persistent HP infection, we have worked out a step strat-
egy for the management of persistent forms of infection with
Helicobacter pylori.
Eighth step strategy
The first step – analysis of each clinical case taking
into account all the circumstances in respect of the diagno-
sis and treatment.
The second step – verification of HP infection by 2
or 3 methods, preferably by culture assessment.
The third step – diagnosis and clarification of asso-
ciated pathology and assessment of endoscopy control.
The fourth step – treatment by administration of an
adequate eradication regimen. Therapy of choice – antibi-
otic testing, quadruple therapy, or alternative therapy – quad-
ruple Levofloxacine - based therapy, or quadruple
Rifabutine plus Levofloxacine therapy.
The fifth step – monitoring of HP infection every six
months.
The sixth step -  registration of patients at increased
risk for gastric cancer.
The seventh step - endoscopic surveillance of pa-
tients with premalignant gastric conditions and lesions.
The eighth step -  dispensary monitoring of patients
with persistent HP infection.
We believe that devised and proposed step strategy
for management of persistent HP infection which covers early
detection of infection, reliable diagnosis,  adequate  and suc-
cessful treatment and dispensary monitoring is a step for-
ward in the prevention of gastric cancer
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